Original story from The University of Texas MD Anderson Cancer Center
Ablative radiation therapy shows promising results for patients with “supermassive” bile duct tumors.
A new study conducted by researchers at The University of Texas MD Anderson Cancer Center suggests that a specialized high-dose form of radiation therapy may significantly improve outcomes for patients with large bile duct tumors in the liver, known as intrahepatic cholangiocarcinoma.
Published in Clinical Cancer Research, the retrospective study was led by Dr. Ethan Ludmir, associate professor, and Dr. Eugene Koay, professor in Gastrointestinal Radiation Oncology.
According to the findings, patients treated with this advanced radiation approach had a median survival more than twice that of those who received chemotherapy alone.
“Traditionally, patients with very large tumors were not treated with radiation due to safety concerns,” said Ludmir. “However, advances in precision delivery over the past 10 to 15 years now allow us to treat these tumors safely at higher doses. This study strongly suggests a significant benefit from this approach.”
Why wasn’t radiation used for these tumors before?
Intrahepatic cholangiocarcinoma affects the bile ducts of the liver, and some tumors can grow larger than 10 centimeters, classifying them as “supermassive.”
Previously, delivering a sufficient radiation dose to treat such tumors was not possible without exceeding the tolerance of healthy liver tissue. Additionally, nearby organs such as the stomach and intestines increased the risk of serious damage.
There was also a long-standing belief that very large tumors were biologically different and less likely to benefit from radiation, even if local control could be achieved.
However, modern radiation techniques at centers like MD Anderson now enable clinicians to deliver ablative doses—high enough to potentially destroy tumors—while precisely targeting the cancer and limiting harm to surrounding tissue.
What makes this study important?
Although some patients at MD Anderson have received this treatment over the past 15 years, this is the first study to formally analyze outcomes.
Because supermassive tumors are relatively rare, the findings provide one of the strongest datasets available for evaluating this approach.
Researchers also compared tumor biology and found no significant differences between large and smaller tumors, suggesting size alone should not limit the use of radiation therapy.
“Molecular and histological analyses showed that these large tumors are not fundamentally different from smaller ones,” said Koay. “This supports the idea that they should respond similarly to ablative radiation.”
Key findings
At a median follow-up of 17.9 months, 34 patients receiving ablative radiation plus chemotherapy had a median overall survival of 28.7 months, compared to 11.9 months in 29 patients treated with chemotherapy alone.
The combination group also experienced lower rates of tumor-related liver failure (12.1% vs. 47.1%).
Comparisons with national cancer database data showed similar survival outcomes for chemotherapy-only patients (11.6 months).
The treatment was generally well tolerated, with no grade 4 or 5 side effects. About 26.5% of patients experienced manageable grade 3 radiation-induced liver disease, and a small number developed late-onset gastrointestinal bleeding that was successfully treated. No other severe adverse effects were reported.
About the Author
